Intellia Therapeutics' CRISPR-Based Therapy for Hereditary Angioedema Accepted for Priority Review by FDA

Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) and granted it Priority Review. If approved, lonvo-z could become the world's first in vivo CRISPR-based therapy and the only one-time treatment for hereditary angioedema (HAE). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027.